Scarica l'app Stockscreener
24.57
0.57%
-0.205
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$24.77
Aprire:
$24.5
Volume 24 ore:
6.29M
Relative Volume:
0.56
Capitalizzazione di mercato:
$9.68B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-2.8139
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-0.53%
1M Prestazione:
-5.31%
6M Prestazione:
-0.93%
1 anno Prestazione:
-33.16%
Intervallo 1D:
$24.27
$25.33
Intervallo di 1 settimana:
$24.18
$27.10
Portata 52W:
$23.04
$48.92
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.56 | 9.68B | 3.14B | -3.36B | -4.03B | -8.73 |
|
ARGX
Argen X Se Adr
|
927.49 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.21 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
196.69 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
377.19 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
705.59 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna, Inc. $MRNA Stock Position Lifted by Letko Brosseau & Associates Inc. - MarketBeat
SG Americas Securities LLC Purchases 487,734 Shares of Moderna, Inc. $MRNA - MarketBeat
Berenberg Adjusts Price Target on Moderna to $28 From $30, Maintains Hold Rating - MarketScreener
Financial Gravity Companies Inc. Takes Position in Moderna, Inc. $MRNA - MarketBeat
Candriam S.C.A. Decreases Stock Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Aviva PLC - MarketBeat
How Moderna Inc. stock benefits from tech adoptionOptions Play & Technical Pattern Alert System - newser.com
How strong is Moderna Inc. stock revenue growthJuly 2025 Closing Moves & Technical Analysis for Trade Confirmation - newser.com
How (MRNA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Moderna (MRNA) Tops S&P 500 Short Interest List in October - GuruFocus
Mitsubishi UFJ Asset Management Co. Ltd. Reduces Stock Position in Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock performs during Fed tightening cyclesJuly 2025 Catalysts & Safe Capital Preservation Plans - Fundação Cultural do Pará
Resona Asset Management Co. Ltd. Reduces Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK - Lohud
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - York Dispatch
Moderna (MRNA) Shareholders Approve Key Proposals at Special Mee - GuruFocus
Moderna Approves Stock Option Exchange Program - TipRanks
Moderna shareholders approve stock option exchange program for employees By Investing.com - Investing.com South Africa
Moderna shareholders approve stock option exchange program for employees - Investing.com
February 2026 Options Now Available For Moderna (MRNA) - Nasdaq
Moderna (MRNA) Stock Surges Amid Partnership Talks and Strong Q3 Results - GuruFocus
What Is Going On With Moderna Stock? - Forbes
5 Insightful Analyst Questions From Moderna's Q3 Earnings Call - Finviz
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire Inc.
Tobam Purchases 55,542 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - Las Cruces Sun-News
5 Insightful Analyst Questions From Moderna’s Q3 Earnings Call - Yahoo Finance
Day 5 of Gains Streak for Moderna Stock with 13% Return (vs. -36% YTD) [11/12/2025] - Trefis
Using Ichimoku Cloud for Moderna Inc. technicalsQuarterly Profit Review & Verified Momentum Watchlists - newser.com
Does Moderna Inc. fit your quant trading modelMarket Weekly Review & Weekly Top Stock Performers List - newser.com
Carisma Therapeutics Inc. SEC 10-Q Report - TradingView
Moderna Inc. recovery potential after sell offCEO Change & High Return Trade Opportunity Guides - newser.com
Moderna, Inc. Hits New 52-Week Low at USD 23.04 Amid Declining Sales - Markets Mojo
Moderna (MRNA) today — Nov. 12, 2025: Special shareholder vote on option exchange, fresh institutional filings, and live stock action - ts2.tech
Moderna (MRNA) Stock: Top Analyst Reiterates ‘Market Perform’ Rating Amid Cost-Cutting Efforts - CoinCentral
Campbell & CO Investment Adviser LLC Takes Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Stock Position Lowered by Bank of New York Mellon Corp - MarketBeat
Acadian Asset Management LLC Purchases 477,072 Shares of Moderna, Inc. $MRNA - MarketBeat
Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know - The Globe and Mail
Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts - ts2.tech
Moderna's Cost-Cutting, Pipeline Catalysts Set Stage for 2026 Upside, UBS Says - MarketScreener
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Commercial Appeal
Moderna to Host Investor Event – Analyst Day - The Augusta Chronicle
Moderna (NASDAQ:MRNA) Price Target Cut to $21.00 by Analysts at Bank of America - MarketBeat
Rothschild & Co Redburn Adjusts Price Target on Moderna to $36 From $53, Maintains Neutral Rating - MarketScreener
Q3 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks - The Globe and Mail
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates - The Marion Star
Is it too late to sell Moderna Inc.2025 Support & Resistance & Stock Market Timing Techniques - newser.com
Moderna (NASDAQ:MRNA) Nasdaq Composite ETF Shapes MedTech Rise - Kalkine Media
What’s next for Moderna Inc. stock priceEarnings Beat & Target Return Focused Picks - newser.com
B of A Securities Maintains Moderna (MRNA) Underperform Recommendation - Nasdaq
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.58%
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):